Fernand Labrie

Publications

Page 4 of 25, showing 50 records out of 1234 total, starting on record 151, ending on 200

Publication Category Year
1084. Couture, J.-F., Legrand, P., Cantin, L., Luu-The, V., Labrie, F., Breton, R. (2004) Loop relaxation, a mechanism which explains the reduced specificity of rabbit 20alpha-hydroxysteroid dehydrogenase, a member of the aldo-keto reductase superfamily. J.Mol. Biol., 339: 89-102. All publications 2004
1083. Dumont, M., Frank, D., Moisan, A.-M., Tranchant, M., Soucy, P., Breton, R., Labrie, F., Tavtigian, S.V., Simard, J. (2004) Structure of primate and rodent orthologs of the prostate cancer susceptibility gene ELAC2. Biochimica et Biophysica Acta, 1679: 230-247. All publications 2004
1082. Bolduc, C., Larose, M., Yoshioka, M., Ye, P., Belleau, P., Labrie, C., Morissette, J., Raymond, V., Labrie, F., St-Amand, J. (2004) Effects of dihydrotestosterone on adipose tissue measured by serial analysis of gene expression. J Mol Endocrinol, 33: 429-444. All publications 2004
1081. Labrie, F. (2003) Hormonal therapy in the management of prostate cancer at all stages of the disease, in: Syrigos, K.N., ed. Prostate Cancer: Biology, Diagnosis and Management, London, UK, Oxford University Press, pp 301-314. All publications 2003
1080. Labrie, F., Cusan, L., Gomez, J.L., Candas, B., Bélanger, A., Luu-The, V., Simard, J. (2003) De la biologie à la clinique: le décès dû au cancer de la prostate peut-il maintenant être une exception? Médecine/Sciences, 19: 910-19. All publications 2003
1079. Simard, J., Dumont, M., Labuda, D., Sinnett, D., Meloche, C., El Alfy, M., Berger, L., Lees, E., Labrie, F., Tavtigian, S.V. (2003) Prostate cancer susceptibility genes: lessons learned and challenges posed. Endocrine Related Cancer, 10: 225-259. All publications 2003
1078. Dimitrakakis, C., Zhou, J., Wang, J., Belanger, A., Labrie, F., Cheng, C., Powell, D., Bondy, C. (2003) A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause, 10: 292-298. All publications 2003
1077. Gutman, M., Couillard, C., Labrie, F., Candas, B., Labrie, C. (2003) Effect of treatment sequence with radiotherapy and the antiestrogen EM-800 on the growth of ZR-75-1 Human mammary carcinoma in nude mice. Int J Cancer, 103: 268-276. All publications 2003
1076. Jensen, J., Kitlen, J., Briand, P., Labrie, F., Lykkesfeldt, A.E. (2003) Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium. J. Steroid Biochem Mol Biol, 84: 469-78. All publications 2003
1075. Labrie, F., El Alfy, M., Berger, L., Labrie, C., Martel, C., Bélanger, A., Candas, B., Pelletier, G. (2003) The combination of a novel SERM with an estrogen protects the mammary gland and uterus in a rodent model: the future of postmenopausal women's health? Endocrinology, 144: 4700-4706. All publications 2003
1074. Labrie, F., Luu-The, V., Labrie, C., Bélanger, A., Simard, J., Lin, S.-X., Pelletier, G. (2003) Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocrine Reviews, 24 (2): 152-182. All publications 2003
1073. Roy, J., Couillard, C., Gutman, M., Labrie, F. (2003) A novel pure SERM achieves complete regression of the majority of human breast cancer tumors in nude mice. Breast Cancer Res Treat, 81: 223-229. All publications 2003
1072. Ciobanu, L.C., Luu-The, V., Martel, C., Labrie, F., Poirier, D. (2003) Inhibition of estrone sulfate-induced uterine growth by potent nonestrogenic steroidal inhibitors of steroid sulfatase. Cancer Res., 63: 6442-6446. All publications 2003
1071. Leblanc, M., Labrie, C., Bélanger, A., Candas, B., Labrie, F. (2003) Bioavailability and pharmacokinetics of dehydroepiandrosterone in the cynomolgus monkey. J Clin Endocrinol Metab, 88 (9): 4293-302. All publications 2003
1070. Lemieux, C., Picard, F., Labrie, F., Richard, D., Deshaies, Y. (2003) The estrogen antagonist EM-652 and dehydroepiandrosterone prevent diet- and ovariectomy-induced obesity. Obes. Res., 11: 477-490. All publications 2003
1069. Mauriège, P., Martel, C., Langin, D., Lacaille, M., Després, J.P., Bélanger, A., Labrie, F., Deshaies, Y. (2003) Chronic effects of dehydroepiandrosterone on rat adipose tissue metabolism. Metabolism, 3: 264-272. All publications 2003
1068. Labrie, F. (2003) Extragonadal synthesis of sex steroïds: Intracrinology. Ann. Endocrinol, 64: 95-107. All publications 2003
1067. Tatchum-Talom, R., Martel, C., Labrie, F., Marette, A. (2003) Acute vascular effects of the selective estrogen receptor modulator EM-652 (SCH 57068) in the rat mesenteric vascular bed. J. of the European Soc. of Cardiology, 57: 535-543. All publications 2003
1066. Sullivan, D.A., Bélanger, A., Cermak, J.M., Bérubé, R., Papas, A.S., Sullivan, R.M., Yamagami, H., Dana, M.R., Labrie, F. (2003) Are women with Sjögren's Syndrome androgen-deficient? Journal of Rheumatology, 30: 2413-2419. All publications 2003
1065. Pelletier, G., Luu-The, V., Li, S., Ren, L., Labrie, F. (2003) Morphological studies of prolactin-secreting cells in estrogen receptor alpha and estrogen receptor beta knockout mice. Neuroendocrinol, 77: 324-333. All publications 2003
1064. Pelletier, G., Luu-The, V., Li, S., Ren, L., Labrie, F. (2003) Sex-related expression of 20alpha-hydroxysteroid dehydrogenase mRNA in the adult mouse. J. Histochem. Cytochem., 51 (11): 1425-1436. All publications 2003
1063. Labrie, F. (2003) Médecin spécialiste en endocrinologie, in : Media, Q., ed. 100 carrières de la santé et des services sociaux, Montréal, Canada, Jobboom les éditions, pp 122. All publications 2003
1062. Gingras, S., Turgeon, C., Brochu, N., Labrie, F., Simard, J. (2003) Characterization and modulation of sex steroid metabolizing activity in normal human keratinocytes in primary culture and hacat cells. J. Steroid Biochem Mol Biol, 87: 167-79. All publications 2003
1061. Couture, J.-F., Legrand, P., Cantin, L., Luu-The, V., Labrie, F., Breton, R, (2003) Human 20alpha-hydroxysteroid dehydrogenase: crystallographic and site-directed mutagenesis studies lead to the identification of an alternative binding site for C21-steroids. J.Mol. Biol., 331: 593-604. All publications 2003
1060. Bélanger, A., Pelletier, G., Labrie, F., Barbier, O., Chouinard, S. (2003) Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans. Trends Endoclinol Metab, 14(10): 473-9. All publications 2003
1059. Akaza, H., Hirao, Y., Labrie, F., Soloway, M.S. (2003) Future prospects for primary hormone therapy in localized and locally advanced prostate cancer. Hinyokika kiyo, Acta Urologica Japonica, 49: 771-7. All publications 2003
1058. Labrie, F. (2002) Androgen blockade in prostate cancer in 2002: major benefits on survival in localized disease. Mol Cell Endocrinol, 198: 77-87. All publications 2002
1057. Labrie, F. (2002) Endocrine-sensitive cancers of the prostate and breast, in: Baster, J., Melmed, S. et New, M., eds: Genetics in Endocrinology, Lippincott-William and Wilkins, pp 607-661. All publications 2002
1056. Labrie, F., Candas, B., Gomez, L.J., Cusan, L. (2002) Can combined androgen blockade provide long term control or possible cure of localized prostate cancer? Urology, 60: 115-119. All publications 2002
1055. Gutman, M., Couillard, S., Roy, J., Labrie, F., Candas, B., Labrie, C. (2002) Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice. International Journal of Cancer, 99: 273-278. All publications 2002
1054. Labrie, F., Bélanger, A., Luu-The, V., Simard, J., Labrie, C. (2002) DHEA replacement therapy as a source of androgens and estrogens at menopause, in: Genazzani, A.R., Petraglia, F. et Artini, P.G., eds: Advances in Gynecological Endocrinology, Florence, Italy, Parthenon Publishing, pp 249-258. All publications 2002
1053. Labrie, F., Labrie, C., Bélanger, A., Simard, J. (2002) Third and fourth generation SERMs, in: Manni, A. et Verderame, M., eds: Selective Estrogen Receptor Modulators: Research and Clinical Applications, Totowa, NJ, Humana Press Inc., pp 167-187. All publications 2002
1052. Leblanc, M., Labrie, C., Bélanger, A., Candas, B., Labrie, F. (2002) Pharmacokinetics of oral dehydroepiandrosterone (DHEA) in the ovariectomised cynomolgus monkey. J. Steroid Biochemistry & Molecular Biology, 81: 159-164. All publications 2002
1051. Bernardi, F., Stomati, M., Luisi, S., Pieri, M., Labrie, F., Geneazzani, A.R. (2002) Effects of the new generation selective estrogen receptor modulator EM-652 and oral administration of estradiol valerate on circulating, brain, and adrenal β-endorphin and allopregnanolone levels in intact fertile and ovariectomized rats. Fertility and Sterility, 77: 1018-1027. All publications 2002
1050. Simoncini, T., Varone, G., Fornari, L., Mannella, P., Labrie, F., Genazzani, A.R. (2002) Genomic and non-genomic mechanisms of nitric oxide synthesis induction in human endothelial cells by a fourth generation selective estrogen receptor modulator. J. Endocrinol, 143: 2052-2061. All publications 2002
1049. Simard, J., Dumont, M., Soucy, P., Labrie, F. (2002) Perspective: Prostate Cancer Susceptibility Genes. Endocrinology, 143: 2029-2040. All publications 2002
1048. Labrie, F., Candas, B. (2002) Letter to the Editor. Re: Does PSA reduce prostate cancer mortality?-Interpreting the Quebec Prostate Cancer Study. CMAJ, 167: 340. All publications 2002
1047. Couture, J.-F., Cantin, L., Legrand, P., Luu-The, V., Labrie, F., Breton, R. (2002) Expression, crystallization and preliminary X-ray analysis of human and rabbit 20alpha-hydroxysteroid dehydrogenases in complex with NADP(H) and various steroid substrates. Acta Cryst. D. Biol. Crystallogr., D58: 135-139. All publications 2002
1046. Crawford, E.D., Miller, G., Labrie, F., Hirano, D., Batuello, J., Globe, M. (2001) Prostate cancer pathology, screening and epidemiology. Reviews in Urology, 3: S2-S10. All publications 2001
1045. Gomella, L.G., Labrie, F., Gamito, E.J., Brawer, M.K. (2001) Prostate cancer: risk assessment and diagnostic approaches. Reviews in Urology, 3: S31-S38. All publications 2001
1044. Labrie, F. (2001) Le cancer de la prostate: blocage combiné des androgènes comme traitement à tous les stades de la maladie. Oncologie, 3: 3-12. All publications 2001
1043. Labrie, F., Candas, B., Cusan, L., Gomez, J.L. (2001) The Laval University screening trial results (Chapter 17), in: Thompson, I.M., Resnick, M.I. et Klein, E.A., eds: Current Clinical Urology, Prostate Cancer Screening, Totowa, NJ, Humana Press Inc., pp 255-279. All publications 2001
1042. Labrie, F., Luu-The, V., Labrie, C., Simard, J. (2001) DHEA and its transformation into androgens and estrogens in peripheral target tissues: Intracrinology. Neuroendocrinologie, 22: 185-212. All publications 2001
1041. Pelletier, G., Luu-The, V., El Alfy, M., Li, S., Labrie, F. (2001) Immunoelectron microscopic localization of 3β-hydroxysteroid dehydrogenase and type 5 17β-hydroxysteroid dehydrogenase in the human prostate and mammary gland. J. Mol. Endocrinol., 26: 11-19. All publications 2001
1040. Roach III, M.J., Thrasher, J.B., Blasko, J., Raben, D., Stone, N., Katz, A., Labrie, F. (2001) Prostatectomy, brachytherapy, intensity modulated radiotherapy, hormonal-radiotherapy, salvae cryosurgery and the role of combined hormonal blokade in the treatment of prostate cancer. Reviews in Urology, 3: S49-S58. All publications 2001
1039. Tavtigian, S.V., Simard, J., Teng, D.H.F., Abtin, V., Baumgard, M., Beck, A., Camp, N.J., Carillo, A.R., Chen, Y., Dayananth, P., Desrochers, M., Dumont, M., Farnham, J.M., Frank, D., Frye, C., Ghaffari, S., Gupte, J.S., Hu, R., Iliev, D., Janecki, T., Kort, E.N., Laity, K.E., Leavitt, A., Leblanc, G., McArthur-Morrison, J., Pederson, A., Penn, B., Peterson, K.T., Reid, J.E., Richards, S., Schroeder, M., Smith, R., Snyder, S.C., Swedlund, B., Swensen, J., Thomas, A., Tranchant, M., Woodland, A.-M., Labrie, F., Skolnick, M.H., Neuhausen, S., Rommens, J., Cannon-Albright, L.A. (2001) A candidate prostate cancer susceptibility gene at chromosome 17p. Nat. Genet., 27: 172-180. All publications 2001
1038. Labrie, F., Bélanger, A., Luu-The, V., Simard, J., Labrie, C. (2001) DHEA replacement therapy as source of androgens and estrogens at menopause, in: Genazani, A.R., Petraglia, F. et Artini, P.G., eds: Advances in Gynecological Endocrinology, London, UK, Parthenon Publishing, pp 249-258. All publications 2001
1037. Labrie, F., Labrie, C., Bélanger, A., Giguère, V., Simard, J., Mérand, Y., Gauthier, S., Luu-The, V., Candas, B., Martel, C.E.A. (2001) Pure selective estrogen receptor modulators, new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activities, in: Scolnick, E.M., ed. Advances in Protein Chemistry, San Diego, CA, Academic Press, pp 293-368. All publications 2001
1036. Labrie, F., Labrie, C., Bélanger, A., Simard, J., Giguère, V., Tremblay, A., Tremblay, G. (2001) EM-652 (SCH 57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium. J. Steroid Biochem. Mol. Biol., 79: 213-225. All publications 2001
1035. Labrie, F., Simard, A.R., Labrie, C., Bélanger, A. (2001) EM-652 (SCH57068) a pure SERM in the mammary gland and endometrium. Référence en Gynécologie Obstétrique, 8: 331-336. All publications 2001
<< previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 next >>

Biography  |  Publications  |  Scientific Conferences  |  Selected Slide Presentations  |  Awards